Bench to Bed Evidences for Pharmacokinetic and Pharmacodynamic Interactions Involving Oseltamivir and Chinese Medicine

Table 3

Summary of pharmacokinetic parameters following the administration of (a) WM and (b) WM + CMF1 in Chinese male healthy volunteers.

Analytes	PK parametersa,b	Treatment
		WM (𝑛=14)	WM + CMF1 (𝑛=14)
OA	𝐶trough (ng/mL)	1.86±1.72	2.36±0.83
	𝐶max (ng/mL)	67.9±27.1	51.3±17.4
	AUC0--12h (ng·h/mL)	134.4±41.1	127.8±28.8
	𝑇max (h)	0.61±0.21	0.93±0.51
	𝑇1/2 (h)	1.98±0.40	2.94±0.74
	12 h Cum. amt. in urine (𝜇g)	2883±985	2810±743
	Renal clearance (L/h)	22.1±6.8	22.4±5.2
OC	𝐶trough (ng/mL)	206.9±67.7	195.3±51.2
	𝐶max (ng/mL)	535.6±102.2	487.4±82.7
	AUC0--12h (ng·h/mL)	4585±1155	4142±783
	𝑇max (h)	4.21±0.97	3.50±0.94
	𝑇1/2 (h)	5.16±1.27	5.70±1.35
	12 h Cum. amt. in urine (𝜇g)	72851±15312	62087±10741
	Renal clearance (L/h)	16.3±3.8	15.4±3.2
OC/OA	AUC0--12h ratio	37.0±14.4	34.2±10.7
	12 h Cum. amt. ratio	27.2±8.4	23.2±5.9

^a𝐶_trough: plasma concentration of analyte at 12 h postdose; 𝐶_max: plasma concentration of analyte corresponding to 𝑇_max; 𝑇_max: time of maximum observed concentration; AUC_0--12h: area under curve from 0 to 12 h; 𝑇_1/2: Terminal half-life; Cum. amt.: cumulative amount.
^bData was presented as arithmetic mean ± SD.